Lista de obras -

A new polymorphism in the type II deiodinase gene is associated with circulating thyroid hormone parameters.

artículo científico publicado en 2005

A polymorphic CA repeat in the promoter region of the insulin-like growth factor-I (IGF-I) gene

artículo científico publicado en 2003

A polymorphism in the IGF-I gene influences the age-related decline in circulating total IGF-I levels

scientific article published on 01 February 2003

A polymorphism in type I deiodinase is associated with circulating free insulin-like growth factor I levels and body composition in humans.

artículo científico publicado en 2004

Absence or low IGF-1R-expression in esophageal adenocarcinoma is associated with tumor invasiveness and radicality of surgical resection.

artículo científico publicado en 2015

Acute Effect of Pegvisomant on Cardiovascular Risk Markers in Healthy Men: Implications for the Pathogenesis of Atherosclerosis in GH Deficiency ⬇️

artículo científico publicado el 1 de noviembre de 2001

Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly ⬇️

artículo científico publicado el 10 de enero de 2012

Administration of acylated ghrelin reduces insulin sensitivity, whereas the combination of acylated plus unacylated ghrelin strongly improves insulin sensitivity.

artículo científico publicado en 2004

Advantages and disadvantages of GH/IGF-I combination treatment.

artículo científico publicado en 2008

An IGF-I gene polymorphism modifies the risk of developing persistent microalbuminuria in type 1 diabetes

article

An early diagnostic tool for diabetic peripheral neuropathy in rats

artículo científico publicado en 2015

An igf-I gene polymorphism modifies the risk of diabetic retinopathy

artículo científico publicado en 2006

An insulin-like growth factor-I promoter polymorphism is associated with increased mortality in subjects with myocardial infarction in an elderly Caucasian population

artículo científico publicado en 2006

Association of the ER22/23EK polymorphism in the glucocorticoid receptor gene with survival and C-reactive protein levels in elderly men.

artículo científico publicado en 2004

Bioactive rather than total IGF-I is involved in acute responses to nutritional interventions in CAPD patients.

artículo científico publicado en 2009

Blockade of the growth hormone (GH) receptor unmasks rapid GH-releasing peptide-6-mediated tissue-specific insulin resistance

artículo científico publicado en 2001

Building the Case for Insulin-Like Growth Factor Receptor-I Involvement in Thyroid-Associated Ophthalmopathy.

artículo científico publicado en 2016

Changes in circulating IGF1 receptor stimulating activity do not parallel changes in total IGF1 during GH treatment of GH-deficient adults

artículo científico publicado en 2015

Circulating IgGs may modulate IGF-I receptor stimulating activity in a subset of patients with Graves' ophthalmopathy.

artículo científico publicado en 2013

Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population-based screening

scientific article published on 01 September 2004

Circulating insulin-like growth factors may contribute substantially to insulin receptor isoform A and insulin receptor isoform B signalling.

artículo científico publicado en 2012

Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients.

artículo científico publicado en 2009

Concentrations of Insulin Glargine and Its Metabolites During Long-Term Insulin Therapy in Type 2 Diabetic Patients and Comparison of Effects of Insulin Glargine, Its Metabolites, IGF-I, and Human Insulin on Insulin and IGF-I Receptor Signaling ⬇️

artículo científico publicado el 8 de abril de 2013

Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient

artículo científico publicado en 2001

Correction: An Early Diagnostic Tool for Diabetic Peripheral Neuropathy in Rats

artículo científico publicado en 2015

Diagnosing metabolic syndrome in craniopharyngioma patients: body composition versus BMI

scientific article published on 01 August 2019

Disagreement in normative IGF-I levels may lead to different clinical interpretations and GH dose adjustments in GH deficiency.

artículo científico publicado en 2017

Effect of Intensive Insulin Therapy on the Somatotropic Axis of Critically Ill Children

artículo científico publicado en 2011

Effects of Somatostatin Analogs and Dopamine Agonists on Insulin-Like Growth Factor 2-Induced Insulin Receptor Isoform A Activation by Gastroenteropancreatic Neuroendocrine Tumor Cells

artículo científico publicado en 2016

Effects of chronic slow release-lanreotide treatment on insulin-like growth factor system and metabolic parameters in acromegalic patients.

artículo científico publicado en 2011

Effects of fasting and pegvisomant on the GH‐releasing hormone and GH‐releasing peptide‐6 stimulated growth hormone secretion ⬇️

artículo científico publicado el 1 de octubre de 2001

Effects of the Renin-Angiotensin System Genes and Salt Sensitivity Genes on Blood Pressure and Atherosclerosis in the Total Population and Patients With Type 2 Diabetes

article

Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study).

artículo científico publicado en 2017

Efficacy and Safety of switching to Pasireotide in Acromegaly Patients controlled with Pegvisomant and Somatostatin Analogues: PAPE extension study

scientific article published on 12 October 2018

Efficacy and safety of bariatric surgery for craniopharyngioma-related hypothalamic obesity: a matched case–control study with 2 years of follow-up

artículo científico publicado en 2016

Endocrine responses to ghrelin in adult patients with isolated childhood-onset growth hormone deficiency.

artículo científico publicado en 2002

Endogenous hormones and carotid atherosclerosis in elderly men.

artículo científico publicado en 2003

Fractures, Bone Mineral Density, and Final Height in Craniopharyngioma Patients with a Follow-up of 16 Years

scientific article published on 01 April 2020

Free and Total Insulin-Like Growth Factor I (IGF-I), IGF-Binding Protein-1 (IGFBP-1), and IGFBP-3 and Their Relationships to the Presence of Diabetic Retinopathy and Glomerular Hyperfiltration in Insulin-Dependent Diabetes Mellitus1 ⬇️

artículo científico publicado el 1 de septiembre de 1997

High IGFBP2 levels are not only associated with a better metabolic risk profile but also with increased mortality in elderly men.

artículo científico publicado en 2012

High bone mineral density and fracture risk in type 2 diabetes as skeletal complications of inadequate glucose control: the Rotterdam Study

artículo científico publicado en 2013

How to Position Pasireotide LAR Treatment in Acromegaly

artículo científico publicado en 2019

IGF-1 CA repeat variant and breast cancer risk in postmenopausal women

artículo científico publicado en 2007

IGF-I Bioactivity Better Reflects Growth Hormone Deficiency than Total IGF-I ⬇️

artículo científico publicado el 11 de mayo de 2011

IGF-I bioactivity might reflect different aspects of quality of life than total IGF-I in GH-deficient patients during GH treatment.

artículo científico publicado en 2013

IGF-IR Targeted Therapy: Past, Present and Future

artículo científico publicado en 2014

Impact of Physical Exercise on Endocrine Aging

artículo científico publicado en 2016

Insulin analogs and cancer: a note of caution

artículo científico publicado en 2014

Insulin and its analogues and their affinities for the IGF1 receptor.

artículo científico

Insulin glargine is more potent in activating the human IGF-I receptor than human insulin and insulin detemir.

artículo científico publicado en 2010

Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy

scientific article published on 01 February 2019

Insulin-like growth factor I: pros and cons of a bioassay.

artículo científico publicado en 2011

Insulin-like growth factor-I gene polymorphism and risk of heart failure (the Rotterdam Study)

scientific article published on 01 August 2004

Intravenous glucose administration in fasting rats has differential effects on acylated and unacylated ghrelin in the portal and systemic circulation: a comparison between portal and peripheral concentrations in anesthetized rats.

artículo científico publicado en 2007

Lack of associations between serum leptin, a polymorphism in the gene for the beta 3-adrenergic receptor and glucose tolerance in the Dutch population.

artículo científico publicado en 1998

Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly.

artículo científico publicado en 2005

Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly

scientific article published on 25 September 2007

Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly

artículo científico publicado en 2014

Low circulating insulin-like growth factor I bioactivity in elderly men is associated with increased mortality

artículo científico publicado en 2008

Methylation of IGF2 regulatory regions to diagnose adrenocortical carcinomas

artículo científico publicado en 2016

Modifying Effects of Glucose and Insulin/Insulin-Like Growth Factors on Colon Cancer Cells

artículo científico publicado en 2021

New Insights from IGF-IR Stimulating Activity Analyses: Pathological Considerations

scientific article published on 02 April 2020

Normal values of circulating insulin-like growth factor-I bioactivity in the healthy population: comparison with five widely used IGF-I immunoassays

scientific article published on 08 April 2008

Pasireotide responsiveness in acromegaly is mainly driven by somatostatin receptor subtype 2 expression

artículo científico publicado en 2019

Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels.

artículo científico publicado en 2005

Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant.

artículo científico publicado en 2008

Response to Krieger et al. re: "TSHR/IGF-1R Cross-Talk, Not IGF-1R Stimulating Antibodies, Mediates Graves' Ophthalmopathy Pathogenesis" (Thyroid 2017;27:746-747)

artículo científico publicado en 2017

Serum free IGF-I, total IGF-I, IGFBP-1 and IGFBP-3 levels in an elderly population: relation to age and sex steroid levels.

artículo científico publicado en 1998

Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.

artículo científico publicado en 2016

The 'bio-assay' quality of life might be a better marker of disease activity in acromegalic patients than serum total IGF-I concentrations.

artículo científico publicado en 2005

The -Adducin Gene Is Associated With Macrovascular Complications and Mortality in Patients With Type 2 Diabetes

article

The IGSF1 deficiency syndrome: characteristics of male and female patients

artículo científico publicado en 2013

The insulin-like growth factor-I receptor stimulating activity (IRSA) in health and disease

artículo científico publicado en 2019

The introduction of the IDS-iSYS total IGF-1 assay may have far-reaching consequences for diagnosis and treatment of GH deficiency.

artículo científico publicado en 2015

The metabolic syndrome and its components in 178 patients treated for craniopharyngioma after 16 years of follow-up.

artículo científico publicado en 2017

Unacylated ghrelin acts as a potent insulin secretagogue in glucose-stimulated conditions

scientific article published on 19 June 2007

Unacylated ghrelin is active on the INS-1E rat insulinoma cell line independently of the growth hormone secretagogue receptor type 1a and the corticotropin releasing factor 2 receptor.

artículo científico publicado en 2006

Very long-term sequelae of craniopharyngioma.

artículo científico publicado en 2017

What is the efficacy of switching to weekly pegvisomant in acromegaly patients well controlled on combination therapy?

scientific article published on 22 February 2016

Lista de obras de

A new polymorphism in the type II deiodinase gene is associated with circulating thyroid hormone parameters.

A polymorphic CA repeat in the promoter region of the insulin-like growth factor-I (IGF-I) gene

A polymorphism in the IGF-I gene influences the age-related decline in circulating total IGF-I levels

A polymorphism in type I deiodinase is associated with circulating free insulin-like growth factor I levels and body composition in humans.

Absence or low IGF-1R-expression in esophageal adenocarcinoma is associated with tumor invasiveness and radicality of surgical resection.

Acute Effect of Pegvisomant on Cardiovascular Risk Markers in Healthy Men: Implications for the Pathogenesis of Atherosclerosis in GH Deficiency ⬇️

Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly ⬇️

Administration of acylated ghrelin reduces insulin sensitivity, whereas the combination of acylated plus unacylated ghrelin strongly improves insulin sensitivity.

Advantages and disadvantages of GH/IGF-I combination treatment.

An IGF-I gene polymorphism modifies the risk of developing persistent microalbuminuria in type 1 diabetes

An early diagnostic tool for diabetic peripheral neuropathy in rats

An igf-I gene polymorphism modifies the risk of diabetic retinopathy

An insulin-like growth factor-I promoter polymorphism is associated with increased mortality in subjects with myocardial infarction in an elderly Caucasian population

Association of the ER22/23EK polymorphism in the glucocorticoid receptor gene with survival and C-reactive protein levels in elderly men.

Bioactive rather than total IGF-I is involved in acute responses to nutritional interventions in CAPD patients.

Blockade of the growth hormone (GH) receptor unmasks rapid GH-releasing peptide-6-mediated tissue-specific insulin resistance

Building the Case for Insulin-Like Growth Factor Receptor-I Involvement in Thyroid-Associated Ophthalmopathy.

Changes in circulating IGF1 receptor stimulating activity do not parallel changes in total IGF1 during GH treatment of GH-deficient adults

Circulating IgGs may modulate IGF-I receptor stimulating activity in a subset of patients with Graves' ophthalmopathy.

Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population-based screening

Circulating insulin-like growth factors may contribute substantially to insulin receptor isoform A and insulin receptor isoform B signalling.

Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients.

Concentrations of Insulin Glargine and Its Metabolites During Long-Term Insulin Therapy in Type 2 Diabetic Patients and Comparison of Effects of Insulin Glargine, Its Metabolites, IGF-I, and Human Insulin on Insulin and IGF-I Receptor Signaling ⬇️

Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient

Correction: An Early Diagnostic Tool for Diabetic Peripheral Neuropathy in Rats

Diagnosing metabolic syndrome in craniopharyngioma patients: body composition versus BMI

Disagreement in normative IGF-I levels may lead to different clinical interpretations and GH dose adjustments in GH deficiency.

Effect of Intensive Insulin Therapy on the Somatotropic Axis of Critically Ill Children

Effects of Somatostatin Analogs and Dopamine Agonists on Insulin-Like Growth Factor 2-Induced Insulin Receptor Isoform A Activation by Gastroenteropancreatic Neuroendocrine Tumor Cells

Effects of chronic slow release-lanreotide treatment on insulin-like growth factor system and metabolic parameters in acromegalic patients.

Effects of fasting and pegvisomant on the GH‐releasing hormone and GH‐releasing peptide‐6 stimulated growth hormone secretion ⬇️

Effects of the Renin-Angiotensin System Genes and Salt Sensitivity Genes on Blood Pressure and Atherosclerosis in the Total Population and Patients With Type 2 Diabetes

Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study).

Efficacy and Safety of switching to Pasireotide in Acromegaly Patients controlled with Pegvisomant and Somatostatin Analogues: PAPE extension study

Efficacy and safety of bariatric surgery for craniopharyngioma-related hypothalamic obesity: a matched case–control study with 2 years of follow-up

Endocrine responses to ghrelin in adult patients with isolated childhood-onset growth hormone deficiency.

Endogenous hormones and carotid atherosclerosis in elderly men.

Fractures, Bone Mineral Density, and Final Height in Craniopharyngioma Patients with a Follow-up of 16 Years

Free and Total Insulin-Like Growth Factor I (IGF-I), IGF-Binding Protein-1 (IGFBP-1), and IGFBP-3 and Their Relationships to the Presence of Diabetic Retinopathy and Glomerular Hyperfiltration in Insulin-Dependent Diabetes Mellitus1 ⬇️

High IGFBP2 levels are not only associated with a better metabolic risk profile but also with increased mortality in elderly men.

High bone mineral density and fracture risk in type 2 diabetes as skeletal complications of inadequate glucose control: the Rotterdam Study

How to Position Pasireotide LAR Treatment in Acromegaly

IGF-1 CA repeat variant and breast cancer risk in postmenopausal women

IGF-I Bioactivity Better Reflects Growth Hormone Deficiency than Total IGF-I ⬇️

IGF-I bioactivity might reflect different aspects of quality of life than total IGF-I in GH-deficient patients during GH treatment.

IGF-IR Targeted Therapy: Past, Present and Future

Impact of Physical Exercise on Endocrine Aging

Insulin analogs and cancer: a note of caution

Insulin and its analogues and their affinities for the IGF1 receptor.

Insulin glargine is more potent in activating the human IGF-I receptor than human insulin and insulin detemir.

Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy

Insulin-like growth factor I: pros and cons of a bioassay.

Insulin-like growth factor-I gene polymorphism and risk of heart failure (the Rotterdam Study)

Intravenous glucose administration in fasting rats has differential effects on acylated and unacylated ghrelin in the portal and systemic circulation: a comparison between portal and peripheral concentrations in anesthetized rats.

Lack of associations between serum leptin, a polymorphism in the gene for the beta 3-adrenergic receptor and glucose tolerance in the Dutch population.

Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly.

Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly

Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly

Low circulating insulin-like growth factor I bioactivity in elderly men is associated with increased mortality

Methylation of IGF2 regulatory regions to diagnose adrenocortical carcinomas

Modifying Effects of Glucose and Insulin/Insulin-Like Growth Factors on Colon Cancer Cells

New Insights from IGF-IR Stimulating Activity Analyses: Pathological Considerations

Normal values of circulating insulin-like growth factor-I bioactivity in the healthy population: comparison with five widely used IGF-I immunoassays

Pasireotide responsiveness in acromegaly is mainly driven by somatostatin receptor subtype 2 expression

Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels.

Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant.

Response to Krieger et al. re: "TSHR/IGF-1R Cross-Talk, Not IGF-1R Stimulating Antibodies, Mediates Graves' Ophthalmopathy Pathogenesis" (Thyroid 2017;27:746-747)

Serum free IGF-I, total IGF-I, IGFBP-1 and IGFBP-3 levels in an elderly population: relation to age and sex steroid levels.

Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.

The 'bio-assay' quality of life might be a better marker of disease activity in acromegalic patients than serum total IGF-I concentrations.

The -Adducin Gene Is Associated With Macrovascular Complications and Mortality in Patients With Type 2 Diabetes

The IGSF1 deficiency syndrome: characteristics of male and female patients

The insulin-like growth factor-I receptor stimulating activity (IRSA) in health and disease

The introduction of the IDS-iSYS total IGF-1 assay may have far-reaching consequences for diagnosis and treatment of GH deficiency.

The metabolic syndrome and its components in 178 patients treated for craniopharyngioma after 16 years of follow-up.

Unacylated ghrelin acts as a potent insulin secretagogue in glucose-stimulated conditions

Unacylated ghrelin is active on the INS-1E rat insulinoma cell line independently of the growth hormone secretagogue receptor type 1a and the corticotropin releasing factor 2 receptor.

Very long-term sequelae of craniopharyngioma.

What is the efficacy of switching to weekly pegvisomant in acromegaly patients well controlled on combination therapy?